Process Analytical Technology Market

The global process analytical technology market is projected to reach USD 11.49 billion by 2031 from USD 5.79 billion in 2026, at a CAGR of 14.7% during the forecast period. Market growth is primarily driven by increasing adoption of PAT solutions to support real-time process monitoring and quality assurance, growing implementation of continuous manufacturing in the pharmaceutical and biopharmaceutical industries, stringent regulatory requirements promoting Quality by Design (QbD) and process analytical technology frameworks, and rising investments in bioprocessing and advanced manufacturing technologies. The integration of artificial intelligence, machine learning, and data analytics into process monitoring systems, along with the growing demand for automation and operational efficiency, is further accelerating market growth. However, the high implementation costs of PAT systems, complexities associated with system integration and validation, and a shortage of skilled professionals are expected to restrain market growth to some extent during the forecast period.

The process analytical technology market is competitive in nature, with several big and emerging players equally holding shares of the market. As of 2025, the key players operating in the global process analytical technology market are Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Shimadzu Corporation (Japan), Waters Corporation (US), Bruker Corporation (US), Emerson Electric Co. (US), ABB Ltd. (Switzerland), PerkinElmer, Inc. (US), Mettler-Toledo International Inc. (US), and Carl Zeiss AG (Germany), among others.

To know about the assumptions considered for the study download the pdf brochure

These players have adopted various strategies such as acquisitions, partnerships, and product launches to further expand their presence in the global process analytical technology market. In 2021, a major share of the global process analytical technology market was held by Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), and Waters Corporation (US).

Thermo Fisher Scientific:

The company continues to focus on product innovation and strategic acquisitions as its key growth strategies. In line with its organic growth initiatives, Thermo Fisher Scientific launched several advanced analytical and life sciences solutions in 2025, including the Thermo Scientific Orbitrap Astral Zoom Mass Spectrometer, Orbitrap Excedion Pro Mass Spectrometer, Krios 5 Cryo Transmission Electron Microscope (Cryo-TEM), and the 5L DynaDrive Single-Use Bioreactor, strengthening its portfolio across analytical testing, bioprocessing, and research applications. In addition to product launches, the company actively pursued inorganic growth opportunities to enhance its market position. In February 2025, Thermo Fisher announced the acquisition of Solventum’s Purification & Filtration business for approximately USD 4.1 billion, expanding its bioprocessing and filtration capabilities and strengthening its offerings for pharmaceutical and biotechnology customers. The transaction was completed in September 2025 and integrated into the company’s Life Sciences Solutions segment. These initiatives demonstrate Thermo Fisher’s continued focus on expanding its technology portfolio, strengthening its bioprocessing capabilities, and supporting innovation across life sciences, biopharmaceutical, and analytical markets.

Agilent Technologies:

Agilent Technologies, Inc. focuses on both organic and inorganic growth strategies to strengthen its position in the process analytical technology (PAT) market. The company continues to expand its portfolio through investments in chromatography, mass spectrometry, spectroscopy, and laboratory software solutions that support real-time process monitoring and quality control. In September 2024, Agilent completed the acquisition of BIOVECTRA, a Canada-based CDMO specializing in biologics and highly potent active pharmaceutical ingredients (HPAPIs). The acquisition expanded Agilent’s biopharmaceutical manufacturing capabilities and strengthened its ability to support pharmaceutical and biotechnology customers. Through ongoing product innovation and strategic acquisitions, the company continues to enhance its analytical and process monitoring offerings.

Danaher Corporation:

Danaher Corporation focuses on both organic and inorganic growth strategies to strengthen its position in the process analytical technology (PAT) market. Through its operating companies, including Cytiva, Beckman Coulter Life Sciences, and SCIEX, the company offers a broad portfolio of analytical instruments, bioprocessing solutions, and laboratory technologies that support process monitoring, quality control, and biopharmaceutical manufacturing. In 2025, Danaher continued to expand its life sciences and diagnostics capabilities through product innovation and investments in bioprocessing and analytical technologies. The company also focuses on strategic collaborations and acquisitions to enhance its technology portfolio and strengthen its presence in pharmaceutical and biotechnology end markets. These initiatives demonstrate Danaher’s commitment to advancing analytical workflows, improving manufacturing efficiency, and supporting innovation across life sciences and biopharmaceutical applications.

Related Reports:

Process Analytical Technology Market by Modality (Spectroscopy: Raman, IR; Chromatography: HPLC, GC; MS), Product (Analyzer, Probe, Sensor, Software), Measurement (Online, Inline, At-line), Application (Mfg QA/QC, Drug Discovery) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]